ArticleCancer medicine2025
Third-Generation EGFR-TKIs in T790M-Negative NSCLC After First/Second-Generation EGFR-TKI Failure: A Retrospective Study.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- AcquiredCurrent oncology (Toronto, Ont.) · 2026Article
- Case Report: Short-term disease control with subsequent icotinib therapy in EGFR L858R/C797S, T790M-negative lung adenocarcinoma after osimertinib resistance.Frontiers in oncology · 2026Article
- Advances in understanding the mechanisms underlying acquired resistance to third-generation tyrosine kinase inhibitors in non-small cell lung cancer.Frontiers in cell and developmental biology · 2026Review
- Third-Generation EGFR-TKIs in T790M-Negative NSCLC After First/Second-Generation EGFR-TKI Failure: A Retrospective Study.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeIn non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), only half develop the T790M mutation and thus qualify for the treatment using third-generation EGFR-TKIs. For T790M-negative patients, chemotherapy is the recommended second-line treatment. We compared the efficacy between third-generation EGFR-TKIs and chemotherapy with or without first/second-generation EGFR-TKIs in T790M-negative patients. PATIENTS: This study included T790M-negative patients with EGFR-mutated advanced NSCLC and progressing after first-line treatment with first- or second-generation EGFR-TKIs. Data on clinical characteristics, disease features, and survival were collected, including general conditions, medical history, imaging, histology, and molecular profiling.
resultsOf 82 patients progressing after first- or second-generation EGFR-TKIs without acquiring T790M, 45 received third-generation EGFR-TKIs and 37 received chemotherapy and/or first/second-generation EGFR-TKIs. We found that third-generation EGFR-TKIs led to significantly longer median progression-free survival (mPFS) than other treatments [10.20 months vs. 5.70 months, p = 0.017]. Subgroup analyses indicated that third-generation EGFR-TKIs had similar mPFS to the chemotherapy group but were significantly superior to first/second-generation EGFR-TKIs with or without chemotherapy (10.20 months vs. 4.80 months, p < 0.001; 10.20 months vs. 3.30 months, p = 0.004). The median overall survival (mOS) for patients treated with third-generation EGFR-TKIs and with non-third-generation therapy was 39.80 months (95% CI 23.14 to 56.46) and 32.40 months (95% CI 18.71 to 46.09), p = 0.408, respectively.
conclusionsThird-generation EGFR-TKIs significantly improved mPFS in T790M-negative patients with EGFR-mutated advanced NSCLC and resistant to first-line treatment with first- or second-generation EGFR-TKIs.
trial registrationChiCTR2500096109.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.